Orca Bio

Orca T Account Manager (OTAM) - East / Central / West

Remote

Not SpecifiedCompensation
Mid-level (3 to 4 years), Senior (5 to 8 years)Experience Level
Full TimeJob Type
UnknownVisa
Biotechnology, Pharmaceuticals, HealthcareIndustries

Orca T Account Manager (OTAM)

Position Overview

Orca Bio is a late-stage biotechnology company redefining the transplant process by developing next-generation cell therapies with the goal of providing significantly better survival rates with dramatically fewer risks. The Orca T Account Manager (OTAM) will serve as the primary liaison between Orca Bio and our Authorized Treatment Centers (ATCs). This individual is responsible for building and managing key relationships, supporting clinical site readiness and execution, and driving appropriate use of Orca Bio’s investigational therapies. The OTAM plays a central role in creating a smooth and effective experience for clinical sites, physicians, and other healthcare stakeholders. This is a high-impact, field-based role that requires both strategic thinking and tactical execution. It offers the opportunity to help shape how groundbreaking therapies are delivered to patients who need them most.

Employment Type

Regular, Full-Time Employee

Location Type

Not specified

Salary

Not specified

Essential Duties & Key Responsibilities

Build and Strengthen ATC Relationships

  • Serve as the primary point of contact for assigned ATCs.
  • Develop deep, trusted relationships with decision-makers and stakeholders (including clinicians, operational leads, and executives).
  • Maintain detailed account profiles and insight-driven strategic plans for each site.

Coordinate ATC Operations

  • Lead site onboarding activities including qualification, training, and workflow setup.
  • Serve as the on-the-ground expert for logistics and operational readiness, from patient referral through product administration.
  • Oversee activities related to product handling, including Chain of Identity (COI) and Chain of Custody (COC) compliance.

Support Clinical and Commercial Engagement

  • Educate site personnel on Orca Bio’s investigational therapies, relevant clinical data, and patient eligibility pathways.
  • Work closely with cross-functional teams (Medical Affairs, Clinical Operations, Market Access, Quality, Marketing) to support ATC needs and resolve barriers to treatment.
  • Facilitate communication of the latest scientific and operational updates to ATCs.

Drive Utilization and Insights

  • Analyze account performance and proactively identify opportunities to optimize site engagement and therapy utilization.
  • Gather and share key market insights and feedback from ATCs with internal stakeholders to help inform strategy and operations.
  • Represent Orca Bio at key conferences and professional meetings as needed.

Minimum Qualifications

  • Bachelor’s degree (BA/BS) required.
  • Minimum 8-10 years of experience in healthcare, biotech, or pharmaceutical industry, preferably in cell therapy.
  • Proven track record in account management, preferably in oncology, hematology, or cell therapy.
  • Strong operational understanding of academic medical centers or transplant centers.

Preferred Qualifications

  • Advanced degree in a scientific or business field preferred.
  • MBA or related advanced degree.
  • 5+ years of experience in hematology/oncology or bone marrow transplantation.
  • Previous experience launching or supporting cell or gene therapy products.
  • Familiarity with site operations, patient access pathways, and clinical treatment logistics.
  • Prior experience working in cross-functional field-based teams.

Travel Requirements

  • Willingness to travel up to 50%, including occasional international travel, based on business needs.

Company Information

More than one million people in the United States today are fighting blood cancer. While a traditional allogeneic stem cell transplant has been the best hope for many, the transplant itself can prove fatal or lead to serious conditions, such as graft vs. host disease. Orca Bio is a late-stage biotechnology company redefining the transplant process by developing next-generation cell therapies with the goal of providing significantly better survival rates with dramatically fewer risks. With our purified, high-precision investigational cell therapies we hope to not only replace patients' blood and immune systems with healthy ones, but also restore their lives.

Skills

Relationship Management
Clinical Site Readiness
Logistics
Operational Readiness
Strategic Planning
Stakeholder Engagement
Biotechnology
Cell Therapy

Orca Bio

Develops and commercializes cell therapies

About Orca Bio

Orca Bio operates in the biotechnology sector, specifically focusing on cell therapies that utilize the body's own cells to treat diseases. The company works to enhance these therapies, aiming to make them safer and more effective for patients. Orca Bio's products are primarily used by healthcare providers who administer these therapies to patients as part of their treatment plans. Unlike many competitors, Orca Bio emphasizes a strong team culture and values communication with stakeholders, keeping them informed about the company's progress and developments. The goal of Orca Bio is to improve patient outcomes through advanced cell therapies, addressing conditions that currently have limited treatment options.

Menlo Park, CaliforniaHeadquarters
2016Year Founded
$186.8MTotal Funding
SERIES_DCompany Stage
Biotechnology, HealthcareIndustries
51-200Employees

Benefits

Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Unlimited Paid Time Off
401(k) Retirement Plan
Parental Leave

Risks

Emerging competition from BlueRock Therapeutics in stem cell therapies.
Aspen Neuroscience's advancements in personalized stem cell therapies pose a threat.
Competitors' focus on iPSC-derived therapies may overshadow Orca Bio's offerings.

Differentiation

Orca Bio focuses on high-precision cell therapies for cancer and autoimmune diseases.
Their lead product, Orca-T, shows promising relapse-free survival rates in clinical trials.
Orca Bio's therapies aim to replace diseased blood and immune systems with healthy ones.

Upsides

Orca-T demonstrated 87% relapse-free survival in a Phase 1b/2 trial.
FDA's expedited approval pathways could accelerate Orca Bio's market entry.
Advancements in gene editing enhance the efficacy of Orca Bio's cell therapies.

Land your dream remote job 3x faster with AI